The board of Jubilant Life Sciences, approved the financial results for the quarter ended June 30, 2013. Revenue growth was driven by volume growth in both segments but prices remained under pressure for pharmaceuticals business. The consolidated revenue is up nine per cent Y-o-Y. International revenues has been reported at Rs 999 crores, contributing 74 per cent to the overall mix and up 10 per cent Y-o-Y. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margins has been reported at 17.5 per cent and normalised PAT margins were at 5.1 per cent.
Shyam S Bhartia, Chairman and Managing Director and Hari S Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences said, “We are witnessing a strong underlying momentum in the Life Science Ingredients space, where volume growth has maintained course. The capacity enhancements are helping us scale up at an attractive pace and we are seeing pricing balance getting restored in some of our products. On the other hand the pharma segment is delivering with strong growth in APIs. Going forward, we expect strong operational performance in pharma due to new product launches and geographic expansion and higher capacity utilisation in nutrition ingredients and proprietary products with the uptrend in pricing. The proposed consolidation of the company’s global pharma business and listing the same for equity infusion would result in further growth and reduction of overall consolidated debt of the company.”
EP News Bureau – Mumbai